TRML Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Tourmaline Bio Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 15.68 USD -2%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast TRML stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRML is 59.5 USD with a low forecast of 48.48 USD and a high forecast of 77.7 USD.

TRML Lowest Forecast

Wall Street Target

TRML Average Forecast

Wall Street Target

TRML Highest Forecast

Wall Street Target

209% Upside

279% Upside

396% Upside

The latest public price target was made on Mar 21, 2024 by Yatin Suneja from Guggenheim , who expects TRML stock to rise by 219% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Yatin Suneja Guggenheim	50 USD Upside 219%	1 month ago Mar 21, 2024	Guggenheim reiterates Buy rating on Tourmaline Bio (TRML), "news is likely to increase investors' perceived risk" StreetInsider
Robyn Karnauskas Truist Financial	74 USD Upside 372%	1 month ago Mar 20, 2024	Tourmaline Bio (TRML) PT Raised to $74 at Truist Securities, 'have increased conviction for the opportunity for TOUR006' StreetInsider
Roger Song Jefferies	72 USD Upside 359%	1 month ago Mar 20, 2024	Tourmaline Bio (TRML) PT Raised to $72 at Jefferies StreetInsider

Price Target	50 USD
Upside/Downside	219%

Price Target	74 USD
Upside/Downside	372%

Price Target	72 USD
Upside/Downside	359%

Biogen Inc

48% Upside

United Therapeutics Corp

27% Upside

Oryzon Genomics SA

226% Upside

Anika Therapeutics Inc

21% Upside

Biogen Inc

48% Upside

United Therapeutics Corp

27% Upside

Oryzon Genomics SA

226% Upside

Anika Therapeutics Inc

21% Upside

Zura Bio Ltd

279% Upside

Y-mAbs Therapeutics Inc

49% Upside

Beijing Strong Biotechnologies Inc

19% Upside

Genfit SA

203% Upside

Revenue
Forecast

N/A

N/A

N/A

N/A

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-4%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-85%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for TRML is 59.5 USD with a low forecast of 48.48 USD and a high forecast of 77.7 USD.

Join more than 132,500+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.